The study compared two approaches for preparing people with leukemia for stem cell transplantation.

The current way of measuring radiation dermatitis severity does not account for variability in skin of color.

The Phase 1 Developmental Therapeutics Program assesses treatments in the earliest stage of clinical trials.

Dr. William C. Huang says the agent could be a paradigm-changing method of treating some bladder cancers.

A new study shows that combining mRNA and pembrolizumab creates a vaccine effective against melanoma.

More than 70 percent of people in the clinical trial responded to the drug.

The PRECEDE Consortium aims to increase the 5-year survival rate to 50 percent within the next 10 years.

Advances in drug design are making gains against a difficult to treat cancer.

Dr. Nina D’Abreo says people should expect one-on-one care when they seek treatment with her.

Dr. Michael Shusterman says monitoring ctDNA is one way to determine who can forgo additional treatment.